Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur

Executive Summary

Cancer drug trials that are statistically "underpowered" because of their small size are becoming a "major problem," FDA Oncologic Drug Products Division Director Richard Pazdur, MD, told a joint American Society of Clinical Oncology/FDA workshop April 15 in Alexandria, Va

You may also be interested in...



FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards

FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.

FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards

FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.

Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says

An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel